The clinical benefit conferred by the centromeric-B KIR motif could result from the presence of activating KIRs 2DS2 and 2DS3. These two activating KIRs have no detectable avidity for HLA class I [50,51], but may recognize different ligands associated with infection or tumor transformation. The gene discussed is KIR3DL1; the disease is infection.